New data on CLEAR CARE® PLUS Cleaning and Disinfecting Solution presented at Annual Meeting of ARVO
May 07, 2015
New data on CLEAR CARE® PLUSSolution presented during the 2015 Annual Meeting for The Association for Research in Vision and Ophthalmology (ARVO), May 3-7, in Denver, Colorado
Study results demonstrate that CLEAR CARE PLUS was effective at eliminating or reducing populations of relevant clinical ocular isolates and Acanthamoeba spp
Results from another study indicate that HydraGlyde®Moisture Matrix technology, the specific diblock copolymer wetting technology found in the new solution has a positive impact on the lubrication properties of silicone hydrogel lenses
Fort Worth, Texas, May 07, 2015– Alcon, the global leader in eye care and the second largest division of Novartis, announced the presentation of two posters highlighting the effectiveness of CLEAR CARE® PLUS Solution at the Annual Meeting for The Association for Research in Vision and Ophthalmology (ARVO), May 3-7, in Denver, Colorado.
"The efficacy of lens care disinfecting solutions is only required to be evaluated against laboratory-maintained organisms derived from ocular disease. A more comprehensive approach is to include clinically relevant ocular pathogens to provide a broader assessment of efficacy," said Manal M. Gabriel, PhD., Project Lead for R&D Vision Care Microbiology at Alcon. "In this expanded evaluation, CLEAR CARE PLUS Solution demonstrated a high level of activity against both the standard laboratory strains and clinically relevant strains of bacteria, yeast, and Acanthamoeba." Study Details:
In a study conducted by Alcon, CLEAR CARE PLUS was evaluated against clinical bacteria and yeast isolates obtained from patients with microbial keratitis or corneal ulcers using the International Organization for Standardization (ISO) 14729 Stand-Alone Test method for disinfection efficacy. The clinical isolates may be more resistant to disinfecting solutions than traditional ISO panel organisms. After 6 hrs of exposure, CLEAR CARE PLUS demonstrated an average of > 99.99% reduction of bacterial clinical isolates for each of the six strains tested and > 99% reduction of yeast clinical isolates. In addition, the new solution demonstrated an average of > 99.9% reduction in Acanthamoebatrophozoites and 99% reduction of Acanthamoeba cysts. These results demonstrate that CLEAR CARE PLUS is effective at reducing populations of clinically relevant ocular isolates, including Acanthamoeba.
A study sponsored by Alcon used X-ray photoelectron spectroscopy (XPS) and atomic force microscopy (AFM) to evaluate the degree of molecular interactions of the HydraGlyde® Moisture Matrix technology used in CLEAR CARE PLUS with the surface of a defined set of silicone hydrogel contact lenses. The presence of the HydraGlyde Moisture Matrix technology significantly reduced friction at the surface of the balafilcon A (85% reduction) and lotrafilcon B (82% reduction) silicon hydrogel lenses. These results indicate that the HydraGlyde Moisture Matrix technology used in CLEAR CARE PLUS can have a positive impact on the lubrication properties of these silicone hydrogel contact lenses.
About CLEAR CARE PLUS Solution
The CLEAR CARE and CLEAR CARE PLUS Cleaning & Disinfecting Solutions (AOSEPT PLUS and AOSEPT® PLUS with HydraGlyde Moisture Matrix technology in some markets) contain 3% hydrogen peroxide and are indicated for use with soft (hydrophilic) and rigid gas permeable (RGP) contact lenses. During the cleaning process, the hydrogen peroxide is neutralized in the special lens case provided to leave behind a preservative-free saline solution that is gentle on the eyes. Cleaned and disinfected lenses can be stored in the neutralized solution in the unopened lens case up to seven days.
CLEAR CARE and CLEAR CARE PLUS require patients to follow special cleaning and disinfecting instructions, including ensuring the lenses remain in the special lens case for at least six hours to allow the hydrogen peroxide to neutralize. Special care is needed to follow directions to avoid accidental misuse.
Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. Alcon’s three businesses, Surgical, Pharmaceutical and Vision Care, offer the widest spectrum of eye care products in the world. Alcon is the second largest division of the Novartis Group, with pro-forma sales of USD 10.8 billion in 2014.
Headquartered in Fort Worth, Texas, USA, Alcon has more than 25,000 employees worldwide, operations in 75 countries and products available in 180 markets.
Beth Bentley Alcon Global Communications
Elizabeth Harness Murphy Alcon Global Communications
1. Perry, S.S., Rex, J., Rudy, A., and Lemp, J. Compositional and Frictional Analysis of a Copolymer Solution Treatment of Silicone Hydrogel Contact Lens Surfaces. Presented at the Annual Meeting for The Association for Research in Vision and Ophthalmology (ARVO), May 3-7, 2015, in Denver, Colorado.
2. Gabriel, M. Ph.D., McAnally, C., Walters, R., Clark, L., Crary, M., Bartell, J., and Catalone, B. Biocidal Efficacy of a New Hydrogen Peroxide Disinfecting Solution Against Clinical Bacterial and Yeast Isolates, and Acanthamoeba Species. Presented at the Annual Meeting for The Association for Research in Vision and Ophthalmology (ARVO), May 3-7, in Denver, Colorado.